SUPERSTRING CAPITAL MANAGEMENT LP — 13F Holdings & Portfolio
CIK 1931118 · latest 13F-HR filed 2026-08-14
SUPERSTRING CAPITAL MANAGEMENT LP manages $158.4M in 13F-reported U.S. long-equity assets across 32 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are COGT (8.39%), AXSM (8.33%), GMAB (7.47%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 8 new positions and exited 11; 14 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 63.8%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 30, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| DOHERTY, MARK, PETER Control | CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER since Mar 2026 | Less than 5% | Individual |
| SUPERSTRING CAPITAL FUND GP LLC Control | GENERAL PARTNER since Oct 2019 | Less than 5% | Domestic Entity |
| Ting, Guo Control | MANAGING PARTNER since Oct 2019 | 75% or more | Individual |
| Ting, Guo Control Indirect owner via SUPERSTRING CAPITAL FUND GP LLC | MANAGING PARTNER since Oct 2019 | 75% or more | Individual |
Ownership & leadership changes · 2 filings with changes since Oct 18, 2019
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedSONG, GEORGE, BENEDICT · CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Oct 2019
- AddedDOHERTY, MARK, PETER · CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER · Less than 5% · control person
- ChangedSUPERSTRING CAPITAL FUND GP LLC · ownership 75% or more → Less than 5%
- ListedSONG, GEORGE, BENEDICT · CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedSUPERSTRING CAPITAL FUND GP LLC · GENERAL PARTNER · 75% or more · control person
- ListedTing, Guo · MANAGING PARTNER · 75% or more · control person
- ListedTing, Guo · MANAGING PARTNER · 75% or more · indirect via SUPERSTRING CAPITAL FUND GP LLC · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- AXSOME THERAPEUTICS INC.$11.3M +596.1%
- TREVI THERAPEUTICS INC$6.8M +225.8%
- GENMAB A/S$6.6M +124.1%
- CLIMB BIO INC$5.4M +397.9%
- CELLDEX THERAPEUTICS INC NEW$5.0M +87.4%
Top Trims
- SIONNA THERAPEUTICS INC-$2.9M -50.9%
- SAVARA INC-$2.6M -30.5%
- VAXCYTE INC-$2.5M -39.5%
- ZAI LAB LTD-$2.2M -42.9%
- IMMUNOVANT INC-$854.5K -9.6%
New Positions
- REVOLUTION MEDICINES INC$9.6M
- BEONE MEDICINES LTD$3.5M
- CYBIN INC$1.4M
- KINIKSA PHARMACEUTICALS INTL$1.2M
- ROIVANT SCIENCES LTD$906.8K
Exited Positions
- SUMMIT THERAPEUTICS INC$16.9M
- VERTEX PHARMACEUTICALS INC$4.9M
- IQVIA HLDGS INC$4.4M
- ARVINAS INC$3.3M
- ORUKA THERAPEUTICS INC$3.1M
SUPERSTRING CAPITAL MANAGEMENT LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $13.3M | 8.39% | 343,284 | SH |
| 2 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $13.2M | 8.33% | 53,916 | SH |
| 3 | GENMAB A/S | GMAB | 372303206 | $11.8M | 7.47% | 430,600 | SH |
| 4 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $10.7M | 6.76% | 287,583 | SH |
| 5 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $9.8M | 6.17% | 524,224 | SH |
| 6 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $9.6M | 6.04% | 51,053 | SH |
| 7 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $8.9M | 5.59% | 188,282 | SH |
| 8 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $8.7M | 5.49% | 853,685 | SH |
| 9 | IMMUNOVANT INC | IMVT | 45258J102 | $8.0M | 5.07% | 208,368 | SH |
| 10 | UROGEN PHARMA LTD | URGN | M96088105 | $7.0M | 4.45% | 191,313 | SH |
| 11 | CLIMB BIO INC | CLYM | 28658R106 | $6.8M | 4.29% | 521,082 | SH |
| 12 | ADLAI NORTYE LTD | ANL | 00704R109 | $6.4M | 4.01% | 552,501 | SH |
| 13 | SAVARA INC | SVRA | 805111101 | $6.0M | 3.80% | 977,460 | SH |
| 14 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $4.5M | 2.84% | 125,432 | SH |
| 15 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $4.4M | 2.78% | 406,077 | SH |
| 16 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $3.9M | 2.45% | 7,172 | SH |
| 17 | VAXCYTE INC | PCVX | 92243G108 | $3.9M | 2.45% | 66,793 | SH |
| 18 | BEONE MEDICINES LTD | ONC | 07725L102 | $3.5M | 2.21% | 12,273 | SH |
| 19 | CABALETTA BIO INC | CABA | 12674W109 | $3.5M | 2.20% | 1,278,652 | SH |
| 20 | ZAI LAB LTD | ZLAB | 98887Q104 | $3.0M | 1.87% | 155,813 | SH |
| 21 | SIONNA THERAPEUTICS INC | SION | 829401108 | $2.8M | 1.75% | 63,156 | SH |
| 22 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $2.1M | 1.35% | 30,456 | SH |
| 23 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $1.4M | 0.86% | 257,675 | SH |
| 24 | CYBIN INC | HELP | 23256X407 | $1.4M | 0.85% | 204,424 | SH |
| 25 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $1.2M | 0.76% | 18,867 | SH |
| 26 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $906.8K | 0.57% | 25,623 | SH |
| 27 | TONIX PHARMACEUTICALS HLDG C | TNXP | 890260839 | $812.1K | 0.51% | 63,648 | SH |
| 28 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $464.0K | 0.29% | 121,457 | SH |
| 29 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $354.4K | 0.22% | 14,175 | SH |
| 30 | BOUNDLESS BIO INC | BOLD | 10170A100 | $138.4K | 0.09% | 55,356 | SH |
| 31 | BIOMEA FUSION INC | BMEA | 09077A106 | $85.3K | 0.05% | 250,000 | SH |
| 32 | VYNE THERAPEUTICS INC | VYNE | 92941V308 | $39.9K | 0.03% | 61,269 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $158.4M | 32 | 0001931118-26-000009 |
| 2026-03-31 | 2026-05-14 | $140.0M | 35 | 0001931118-26-000008 |
| 2025-12-31 | 2026-02-17 | $186.8M | 45 | 0001931118-26-000003 |
| 2025-09-30 | 2025-11-14 | $101.5M | 35 | 0001931118-25-000010 |
SUITE 5004
NEW YORK, NY 10022